Companies › Anterogen
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASC (Autologous Adipose-derived Mesenchymal Stem Cells) Autologous adipose-derived mesenchymal stem cells | – | Phase 3 | Crohn's Fistula | – |
| ANT-301 Unclear - biological therapy for knee osteoarthritis | – | Phase 1 | Osteoarthritis, Knee | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04612465 | ASC (Autologous Adipose-derived Mesenchymal Stem Cells) | Phase 3 | Crohn's Fistula | Immunology | Apr 2025 |
| NCT06539429 | ANT-301 | Phase 1 | Osteoarthritis, Knee | Immunology | May 2026 |
No annotated target.
–
ALK-Abelló Aravax VivaTech International AltruBio Qu Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.